Cancer Family
Salivary Gland Neoplasm
CI-CAN-00000343Explore in graph →
Non-malignant74 active trials13 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000343Explore in graph →
Clinical trials
267 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00886132 | A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | completed | Phase 2 | 14 | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01152840 | Study of RAD001 in Adenoid Cystic Carcinoma(ACCRAD001) | completed | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | May 20, 2015 | clinicaltrials |
| NCT00458978 | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00114283 | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01417143 | Dovitinib in Adenoid Cystic Carcinoma | completed | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00507767 | Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00098631 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT00055770 | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00085371 | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | completed | Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00033618 | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00077428 | Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2015source: clinicaltrials